Get the Stockscreener App
0.658
0.58%
0.0038
Pre-market:
.66
0.002
+0.30%
Adicet Bio Inc stock is traded at $0.658, with a volume of 356.05K.
It is up +0.58% in the last 24 hours and down -5.13% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
See More
Previous Close:
$0.6542
Open:
$0.67
24h Volume:
356.05K
Relative Volume:
0.69
Market Cap:
$64.91M
Revenue:
$38.70M
Net Income/Loss:
$-117.88M
P/E Ratio:
-0.3871
EPS:
-1.7
Net Cash Flow:
$-92.84M
1W Performance:
-1.64%
1M Performance:
-5.13%
6M Performance:
-28.18%
1Y Performance:
-55.24%
1-Day Range:
$0.641
$0.6799
1-Week Range:
$0.625
$0.684
52-Week Range:
$0.4471
$1.70
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.658 | 64.91M | 38.70M | -117.88M | -92.84M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.82 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
520.29 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.53 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
267.12 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Adicet Bio Elects Directors and Approves Key Proposals - TipRanks
Adicet Bio, Inc. (NASDAQ:ACET) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Squarepoint Ops LLC Purchases New Shares in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio To Present At Jefferies Global Healthcare Conference; Webcast At 4:20 PM ET - Nasdaq
Northern Trust Corp Acquires 28,153 Shares of Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
ACETAdicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates - Revista ADVFN
Millennium Management LLC Lowers Position in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference - Business Wire
Adicet Bio’s SWOT analysis: gamma-delta T cell therapy stock faces pivotal year - Investing.com
Adicet Bio, Inc. (NASDAQ:ACET) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
Financial Comparison: Adicet Bio (NASDAQ:ACET) & Trevena (NASDAQ:TRVN) - Defense World
Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) Price Target at $7.50 - Defense World
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know - MSN
Adicet Bio (NASDAQ:ACET) Coverage Initiated at StockNews.com - Defense World
Wedbush Comments on Adicet Bio’s Q3 Earnings (NASDAQ:ACET) - Defense World
What is Wedbush’s Estimate for Adicet Bio Q1 Earnings? - Defense World
Adicet Bio Reports Q1 2025 Results and Updates - TipRanks
Marshall Wace LLP Sells 104,894 Shares of Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates - Bluefield Daily Telegraph
ACET's Cash Reserves Expected to Sustain Operations Until Late 2 - GuruFocus
Adicet Bio, Inc. (NASDAQ:ACET) Shares Acquired by JPMorgan Chase & Co. - Defense World
Reviewing Adicet Bio (NASDAQ:ACET) and HUTCHMED (NASDAQ:HCM) - Defense World
Renaissance Technologies LLC Has $882,000 Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - Defense World
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Rating Increased to Hold at StockNews.com - Defense World
Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - BioSpace
Adicet Bio Announces Oral Presentation Highlighting Preclinical Adi-270 Data At The American Society Of Gene And Cell Therapy 28Th Annual Meeting - marketscreener.com
We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate - Yahoo Finance
JMP maintains Market Perform on Adicet Bio shares By Investing.com - Investing.com Canada
JMP maintains Market Perform on Adicet Bio shares - Investing.com
Adicet Bio (NASDAQ:ACET) Now Covered by StockNews.com - Defense World
Adicet Bio appoints Michael Grissinger to its board By Investing.com - Investing.com Canada
Adicet Bio Appoints Michael Grissinger to the Board of Directors - BioSpace
Adicet Bio appoints Michael Grissinger to its board - Investing.com
Adicet Bio Appoints Michael Grissinger to Board - TipRanks
Adicet Bio Appoints Michael Grissinger To The Board Of Directors - marketscreener.com
Adicet Bio Strengthens Board with Ex-Johnson & Johnson VP: Strategic Move for Cell Therapy Pioneer - Stock Titan
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.06%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):